Literature DB >> 31769079

Exact sequential analysis for multiple weighted binomial end points.

Ivair R Silva1, Joshua J Gagne2, Mehdi Najafzadeh2, Martin Kulldorff2.   

Abstract

Sequential analysis is used in clinical trials and postmarket drug safety surveillance to prospectively monitor efficacy and safety to quickly detect benefits and problems, while taking the multiple testing of repeated analyses into account. When there are multiple outcomes, each one may be given a weight corresponding to its severity. This paper introduces an exact sequential analysis procedure for multiple weighted binomial end points; the analysis incorporates a drug's combined benefit and safety profile. It works with a variety of alpha spending functions for continuous, group, or mixed group-continuous sequential analysis. The binomial probabilities may vary over time and do not need to be known a priori. The new method was implemented in the free R Sequential package for both one- and two-tailed sequential analysis. An example is given examining myocardial infarction and major bleeding events in patients who initiated non-steroidal antiinflammatory drugs.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Type I error spending function; sequential testing; variable matching ratio

Year:  2019        PMID: 31769079      PMCID: PMC6984739          DOI: 10.1002/sim.8405

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Exact sequential tests for single samples of discrete responses using spending functions.

Authors:  N Stallard; S Todd
Journal:  Stat Med       Date:  2000-11-30       Impact factor: 2.373

2.  Sequential methods in clinical trials.

Authors:  P ARMITAGE
Journal:  Am J Public Health Nations Health       Date:  1958-10

3.  Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.

Authors:  H M James Hung; Sue-Jane Wang; Robert O'Neill
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

4.  Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance.

Authors:  C E Davis
Journal:  Control Clin Trials       Date:  1997-12

5.  Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.

Authors:  Toshimitsu Hamasaki; Koko Asakura; Scott R Evans; Tomoyuki Sugimoto; Takashi Sozu
Journal:  Stat Biopharm Res       Date:  2015       Impact factor: 1.452

6.  A group sequential Holm procedure with multiple primary endpoints.

Authors:  Yining Ye; Ai Li; Lingyun Liu; Bin Yao
Journal:  Stat Med       Date:  2012-12-14       Impact factor: 2.373

7.  Type I error probability spending for post-market drug and vaccine safety surveillance with binomial data.

Authors:  Ivair R Silva
Journal:  Stat Med       Date:  2017-09-25       Impact factor: 2.373

8.  Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.

Authors:  C Jennison; B W Turnbull
Journal:  Biometrics       Date:  1993-09       Impact factor: 2.571

9.  Procedures for comparing samples with multiple endpoints.

Authors:  P C O'Brien
Journal:  Biometrics       Date:  1984-12       Impact factor: 2.571

10.  Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project.

Authors:  W Katherine Yih; Martin Kulldorff; Bruce H Fireman; Irene M Shui; Edwin M Lewis; Nicola P Klein; James Baggs; Eric S Weintraub; Edward A Belongia; Allison Naleway; Julianne Gee; Richard Platt; Tracy A Lieu
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.